Latest:
Dr. McDonald on the Continued Understanding of Bevacizumab
Dr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Continued Understanding of Bevacizumab
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Donald Weed, MD
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Donna L. Berry, PhD, RN
Latest:
Donna Berry on Patient Communication
Donna L. Berry, PhD, RN, AOCN, FAAN, Director, Phyllis F. Cantor Center for Research in Nursing & Patient Care Services, Dana-Farber Cancer Institute, Associate Professor, Department of Medicine, Harvard Medical School, discusses using technology to communicate with patients
Donna McNamara, MD
Latest:
Dr. Donna McNamara on PARP Inhibitors for Ovarian Cancer Treatment
Donna McNamara, MD, Co-Chief of the Gynecologic Oncology Division and Medical Oncologist for the Breast Oncology Division at the John Theurer Cancer Center, talks about the benefits of PARP inhibitors for women with BRCA1 or BRCA2-mutated, platinum-sensitive ovarian cancer.
Doris Germain, PhD
Latest:
Dr. Germain on Scientific Rationale Behind Bortezomib/Fulvestrant for HR+ Breast Cancer
Doris Germain, PhD, ‎associate professor at Mount Sinai Cancer Institute, discusses the scientific rationale behind a clinical trial comparing fulvestrant alone with bortezomib plus fulvestrant for the treatment of hormone receptor-positive metastatic breast cancer.
Dorothy M. K. Keefe, MD
Latest:
Dr. Keefe on the Role of Supportive Care in Personalized Medicine
Dorothy M. K. Keefe, MD, FRACP, past president, MASCC, director, SA Cancer Service, professor of cancer medicine, University of Adelaide, Australia, discusses the role of supportive care in personalized medicine.
Douglas A. Levine, MD
Latest:
Dr. Levine Discusses a Combination Study in Endometrial Cancer
Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses the randomized NRG Oncology Group 86P study for patients with endometrial cancer.
Douglas B. Chepeha, MD
Latest:
Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer: Implications for Radiotherapy Target Volume Delineation
The ipsilateral parotidean nodes may be at risk of metastatic involvement when bulky ipsilateral level II metastases and multilevel nodal disease are co-existent, possibly due to retrograde lymphatic drainage.
Douglas B. Johnson, MD
Douglas B. Johnson, MD, MSCI, is a professor of medicine in the Division of Hematology/Oncology and leader of the Melanoma Clinical Research Program at Vanderbilt University Medical Center.
Latest:
Dr Johnson on Treatment Gaps With Immunotherapy in Melanoma
Douglas B. Johnson, MD, MSCI, highlighted avenues for improving immunotherapy use in melanoma during Cancer Immunotherapy Awareness Month.
Douglas Kondziolka, MD
Latest:
Dr. Kondziolka Discusses Updates in the Treatment of Brain Metastases
Douglas Kondziolka, MD, MSc, director, Gamma Knife Program, vice chair, Clinical Research, Departments of Neurosurgery and Radiation Oncology, Perlmutter Cancer Center at NYU Langone, discusses updates concerning the treatment of brain metastases.
Douglas Letson MD
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas
Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Douglas Moeller, MD
Latest:
Z-Code Identifiers Give Providers Objective Information About Molecular Tests
Virtually everyone in the clinical laboratory business is now acquainted with Z-code identifiers. Each unique laboratory test should have a unique tracking code, even if more than one Z-code identifier is reported with a corresponding American Medical Association's Current Procedural Terminology (CPT) billing code.